RecruitingPhase 4NCT07163650

Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery

A Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of Efsubaglutide Alfa in Patients Remaining Obese 6 Months After Metabolic Surgery

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Enrollment

60 participants

Start Date

Sep 16, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity Weight Loss Metabolic Surgery

Summary

This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called Diet and exercise guidelines and a drug called Efsubaglutide Alfa Injection for people with metabolic surgery, obesity, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEfsubaglutide Alfa Injection

Efsubaglutide Alfa was injected daily in the morning before meals Subcutaneous injection at a dose of 1 mg/week in the first two weeks, increased to 3 mg/week in week 3, increased to 6 mg/week in week 5, up to 9 mg/2 week in week 13.

BEHAVIORALDiet and exercise guidelines

Participants followed a science-based diet and exercise program intervention.